Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States

Severe Hemophilia ◽

RO4 COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES

Value in Health ◽

10.1016/j.jval.2019.04.1898 ◽

2019 ◽

Vol 22 ◽

pp. S389 ◽

Cited By ~ 2

Author(s):

N. Li ◽

A. Bullement ◽

S. McMordie ◽

A.J. Hatswell ◽

K. Wilson

Keyword(s):

United States ◽

Cost Effectiveness ◽

Prophylactic Treatment ◽

Hemophilia A ◽

The United States ◽

Severe Hemophilia ◽

Faculty Opinions recommendation of Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736028641.793572950 ◽

2020 ◽

Author(s):

John Svigos

Keyword(s):

United States ◽

Cost Effectiveness ◽

Tranexamic Acid ◽

Postpartum Hemorrhage ◽

The United States ◽

Routine Treatment ◽

PND5 Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in the United States

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.393 ◽

2020 ◽

Vol 22 ◽

pp. S75

Author(s):

R. Arjunji ◽

J. Zhou ◽

A. Patel ◽

M.L. Edwards ◽

M. Harvey ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

Spinal Muscular Atrophy ◽

Newborn Screening ◽

Muscular Atrophy ◽

The United States ◽

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Liver International ◽

10.1111/liv.14795 ◽

2021 ◽

Vol 41 (5) ◽

pp. 1097-1104

Author(s):

Feng Wen ◽

Hanrui Zheng ◽

Pengfei Zhang ◽

Weiting Liao ◽

Kexun Zhou ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Systemic Treatment ◽

The United States ◽

Unresectable Hepatocellular Carcinoma

First Line ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States

PLoS ONE ◽

10.1371/journal.pone.0116694 ◽

2015 ◽

Vol 10 (2) ◽

pp. e0116694 ◽

Cited By ~ 4

Author(s):

Dahye L. Song ◽

Frederick L. Altice ◽

Michael M. Copenhaver ◽

Elisa F. Long

Keyword(s):

United States ◽

Cost Effectiveness ◽

Risk Reduction ◽

People Who Inject Drugs ◽

The United States ◽

Evidence Based ◽

Infected People ◽

The Cost-effectiveness Analysis of Nurse-Family Partnership in the United States

Journal of Health Care for the Poor and Underserved ◽

10.1353/hpu.2017.0134 ◽

2017 ◽

Vol 28 (4) ◽

pp. 1578-1597 ◽

Cited By ~ 6

Author(s):

Jinjing Wu ◽

Kelsey S. Dean ◽

Zohn Rosen ◽

Peter A. Muennig

Keyword(s):

United States ◽

Cost Effectiveness ◽

The United States ◽

Effectiveness Analysis ◽

Nurse Family Partnership ◽

Family Partnership ◽

The Cost

Cost-effectiveness Analysis of Extended Extracorporeal Membrane Oxygenation Duration in Newborns with Congenital Diaphragmatic Hernia in the United States

Pediatrics & Neonatology ◽

10.1016/j.pedneo.2021.08.015 ◽

2021 ◽

Author(s):

Hanke Zheng ◽

Cynthia Gong ◽

Rachel Chapman ◽

Leah Yieh ◽

Philippe Friedlich ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

Extracorporeal Membrane Oxygenation ◽

Congenital Diaphragmatic Hernia ◽

Diaphragmatic Hernia ◽

The United States ◽

Membrane Oxygenation ◽

Erratum to: Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis

Journal of Alzheimer s Disease Reports ◽

10.3233/adr-219005 ◽

2021 ◽

pp. 1-1

Keyword(s):

United States ◽

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cost Effectiveness ◽

Cholinesterase Inhibitors ◽

The United States ◽

Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ◽

10.1002/phar.2108 ◽

2018 ◽

Vol 38 (5) ◽

pp. 520-530 ◽

Cited By ~ 7

Author(s):

Patrick M. Zueger ◽

Varun M. Kumar ◽

Rachel L. Harrington ◽

Gianna C. Rigoni ◽

Alicia Atwood ◽

...

Keyword(s):

United States ◽

Heart Failure ◽

Cost Effectiveness ◽

Ejection Fraction ◽

The United States ◽

Reduced Ejection Fraction ◽

A Cost-Effectiveness Analysis of Commonly Used Biologic Drugs for the Treatment of Moderate-To-Severe Psoriasis in the United States

Value in Health ◽

10.1016/j.jval.2018.04.1630 ◽

2018 ◽

Vol 21 ◽

pp. S240

Author(s):

JJ Wu ◽

SR Feldman ◽

S Rastogi ◽

B Menges ◽

M Lingohr-Smith ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

The United States ◽

Severe Psoriasis ◽

Biologic Drugs ◽